SUMO2 Regulates Histone Pre-mRNA Processing by Stabilizing Histone Locus Body Interactions and Promoting U7 snRNP Assembly
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1241289 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR32840510_1.fastq.gz | Fastqsanger.gz | |||
| SRR32840510_2.fastq.gz | Fastqsanger.gz | |||
| SRR32840511_1.fastq.gz | Fastqsanger.gz | |||
| SRR32840511_2.fastq.gz | Fastqsanger.gz | |||
| SRR32840512_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 24 |
Similar Datasets
Project description:Histone mRNAs are the only non-polyadenylated mRNAs in eukaryotic cells and require specialized processing in nuclear organelles known as histone locus bodies (HLBs), where essential processing factors are concentrated, including the U7 snRNP complex. Recent studies have revealed that misregulation of histone pre-mRNA processing can lead to polyadenylation of histone mRNAs and disruption of histone protein homeostasis. Despite the links to human disease, the factors contributing to polyadenylation of histone mRNAs and the mechanisms underlying HLB assembly and U7 snRNP biogenesis remain unclear. Here, we report novel functions of the small ubiquitin-related modifier 2 (SUMO2) in regulating histone pre-mRNA processing. Using a SUMO2 knockout osteosarcoma cell line, we identified a defect in 3’ end cleavage and a global increase in histone mRNA polyadenylation. Subsequent analysis of HLBs revealed increased dynamics and reduced levels of the U7 snRNP complex. By over-expressing U7 snRNP-specific components, Lsm11 and U7 snRNA, we partially rescued U7 snRNP levels and processing defects in SUMO2 knockout cells. Through analysis of Lsm11, we identified a SUMO-interacting motif in its N-terminus required for efficient incorporation into U7 snRNP complexes. Collectively, we demonstrate that SUMO2 promotes histone pre-mRNA 3’ end processing through stabilizing HLB interactions and facilitating U7 snRNP assembly
2025-03-29 | GSE292809 | GEO
Project description:In animal cells, replication-dependent histone pre-mRNAs are cleaved at the 3’ end by U7 snRNP consisting of two core components: a ~60-nucleotide U7 snRNA and a ring of seven proteins, with Lsm10 and Lsm11 replacing the spliceosomal SmD1 and SmD2. Lsm11 interacts with FLASH and together they recruit the endonuclease CPSF73 and other polyadenylation factors, forming catalytically active holo U7 snRNP. Here, we assembled core U7 snRNP bound to FLASH from recombinant components and analyzed its appearance by electron microscopy and ability to support histone pre-mRNA processing in the presence of polyadenylation factors from nuclear extracts. We demonstrate that semi-recombinant holo U7 snRNP reconstituted in this manner has the same composition and functional properties as endogenous U7 snRNP, being capable of accurately cleaving histone pre-mRNAs in a reconstituted in vitro processing reaction. We also demonstrate that the U7-specific Sm ring assembles efficiently in vitro on a spliceosomal Sm site but the resultant semi-recombinant holo U7 snRNP fails to accurately cleave histone pre-mRNAs. This approach offers a unique opportunity to create engineered U7 snRNPs to study the role of various regions in the Sm proteins and U7 snRNA in the biogenesis of a functional holo U7 snRNP.
2019-11-25 | PXD014164 | Pride
Project description:Chromatin immuno-precipitation using SUMO2 (Life Technologies) antibody in U2OS cell line.
2015-08-07 | E-MTAB-3084 | biostudies-arrayexpress
Project description:CRISPR-Cas9 was used to individually knock out SUMO1 and SUMO2 expression in U2OS cells. The transcriptomes of SUMO1 and SUMO2 knockout (KO) cell lines were analyzed using RNA-sequencing.
2021-12-07 | GSE163884 | GEO
Project description:Chromatin immuno-precipitation using SUMO2 (Life Technologies) antibody in MCF10A cell line, treated with epidermal growth factor for 30 minutes.
2019-07-16 | E-MTAB-7759 | biostudies-arrayexpress
Project description:The generation of induced pluripotent stem cells (iPSCs) from differentiated cells following forced expression of Oct4, Klf4, Sox2 and c-Myc (OKSM) is slow and inefficient, suggesting that transcription factors have to overcome somatic barriers that resist cell fate change. Here, we performed an ubiased serial shRNA enrichment screen to identify novel repressors of somatic cell reprogramming into iPSCs. This effort uncovered the sumoylation effector protein Sumo2 as one of the strongest roadblocks to iPSC formation. Depletion of Sumo2 both enhances and accelerates reprogramming, yielding transgene-independent, chimera-competent iPSCs after as little as 36 hours of OKSM expression. We further show that the Sumo2 pathway acts independently of exogenous c-Myc expression and in parallel with small molecule enhancers of reprogramming. Critically, suppression of SUMO2 also promotes the generation of human iPSCs. Together, our results reveal sumoylation as a crucial post-transcriptional mechanism that resists the acquisition of pluripotency from fibroblasts using defined factors. Microarray analysis was performed during reprogramming or of iPSC lines derived upon Sumo2 knockdown Total RNA was isolated from day 6 reprogramming fibroblasts with or without Sumo2 knockdown; as well as stable iPSC clones derived from Sumo2 knockdown fibroblasts.
2016-03-03 | E-GEOD-76699 | biostudies-arrayexpress
Project description:Mounting evidence indicates that small ubiquitin-like modifier (SUMO) conjugation regulates a wide range of neuronal functions and participates in learning and memory processes. Since many SUMO targets are transcription factors as well as other nuclear proteins modulating gene expression and SUMO2 is the predominant SUMO isoform, we aimed to identify how SUMO2 regualtes gene expression in the brain in order to better understand the role of SUMOylation in the brain fucntcion. In this study, we peformed RNA-Seq anaysis on hippocampus from SUMO2 conditional knockout mice.
2020-07-01 | GSE108196 | GEO
Project description:Chromatin immuno-precipitation using SUMO2 (Life Technologies) antibody in the starved U2OS cell line.
2023-06-01 | E-MTAB-12293 | biostudies-arrayexpress
Project description:The generation of induced pluripotent stem cells (iPSCs) from differentiated cells following forced expression of Oct4, Klf4, Sox2 and c-Myc (OKSM) is slow and inefficient, suggesting that transcription factors have to overcome somatic barriers that resist cell fate change. Here, we performed an ubiased serial shRNA enrichment screen to identify novel repressors of somatic cell reprogramming into iPSCs. This effort uncovered the sumoylation effector protein Sumo2 as one of the strongest roadblocks to iPSC formation. Depletion of Sumo2 both enhances and accelerates reprogramming, yielding transgene-independent, chimera-competent iPSCs after as little as 36 hours of OKSM expression. We further show that the Sumo2 pathway acts independently of exogenous c-Myc expression and in parallel with small molecule enhancers of reprogramming. Critically, suppression of SUMO2 also promotes the generation of human iPSCs. Together, our results reveal sumoylation as a crucial post-transcriptional mechanism that resists the acquisition of pluripotency from fibroblasts using defined factors. Microarray analysis was performed during reprogramming or of iPSC lines derived upon Sumo2 knockdown
2016-03-03 | GSE76699 | GEO
Project description:Synovial Sarcoma (SySa) is an aggressive soft tissue sarcoma that accounts for 5 – 10% of all soft tissue sarcomas. Current treatment involves radiation and radical surgery including limb amputation, highlighting the urgent need to develop targeted therapies. We reasoned that transcriptional rewiring by the fusion protein SS18-SSX, the sole oncogenic driver in SySa, creates specific vulnerabilities that can be exploited for treatment. To uncover genes that are selectively essential for SySa, we mined the Dependency Maps (Depmap) database to identify genes that specifically impact the fitness of SySa compared to other tumor cell lines. Targeted CRISPR library screening of select SySa-selective candidates revealed that the small ubiquitin-like modifier 2 (SUMO2) was one of the strongest dependencies both in vitro as well as in vivo. TAK-981, a clinical-stage small molecule SUMO2 inhibitor potently inhibited growth, colony-forming ability, and spheroid formation of SySa cell lines. Strikingly, transcriptomic studies showed that TAK-981 treatment elicited a profound reversal of a gene expression program orchestrated by SS18-SSX fusions. Of note, genetic or pharmacological SUMO2 inhibition reduced global and chromatin levels of the SS18-SSX fusion protein with a concomitant reduction in histone 2A lysine 119 ubiquitination (H2AK119ub), an epigenetic mark that is enhanced by the SySa fusions and plays an important role in SySa pathogenesis. Taken together, our studies identify SUMO2 as a novel, selective vulnerability in SySa. Since SUMO2 inhibitors are currently in Phase 1/2 clinical trials for human cancer, our findings present a novel potential avenue for targeted treatment of synovial sarcoma.
2024-11-06 | GSE274712 | GEO